A biochemistry student is comparing two enzyme inhibitors acting on the same substrate-enzyme system. Inhibitor A increases the apparent Km while leaving Vmax unchanged. Inhibitor B decreases Vmax while leaving Km unchanged. Which kinetic feature best distinguishes competitive inhibition (Inhibitor A) from non-competitive inhibition (Inhibitor B)?

Explanation

## Distinguishing Competitive from Non-Competitive Inhibition **Key Point:** The defining kinetic difference between competitive and non-competitive inhibitors lies in their reversibility by substrate concentration and their effects on Michaelis-Menten parameters. ### Michaelis-Menten Parameter Changes | Feature | Competitive Inhibitor | Non-Competitive Inhibitor | |---------|----------------------|---------------------------| | **Km** | Increases (↑) | Unchanged | | **Vmax** | Unchanged | Decreases (↓) | | **Reversibility** | Reversible by ↑[S] | NOT reversible by ↑[S] | | **Binding site** | Active site (competes with S) | Allosteric site (binds E or ES) | ### Why Reversibility by Substrate Concentration Distinguishes Them Competitive inhibitors bind to the **active site** and compete directly with substrate for enzyme binding. Since both inhibitor and substrate compete for the same site, increasing substrate concentration shifts the equilibrium toward substrate binding, thereby **overcoming the inhibition**. Non-competitive inhibitors bind to a site **other than the active site** (allosteric or to the ES complex). Their binding is independent of substrate concentration; increasing [S] does not displace the inhibitor. The enzyme's catalytic capacity (Vmax) is permanently reduced for any given enzyme molecule that has bound the inhibitor. **High-Yield:** On a Lineweaver-Burk plot: - **Competitive:** Lines intersect on the y-axis (same 1/Vmax, different x-intercepts) - **Non-competitive:** Lines intersect to the left of the y-axis (different 1/Vmax, same x-intercept) **Clinical Pearl:** Acetylcholinesterase inhibitors (e.g., physostigmine) are competitive inhibitors and can be overcome by high acetylcholine concentrations; organophosphate poisoning causes non-competitive phosphorylation, which is essentially irreversible and cannot be overcome by substrate alone. ### Why Other Options Are Incorrect Options 1 and 2 describe the kinetic changes but do NOT distinguish the two types—they merely restate the parameter alterations without identifying the discriminating feature. Option 4 (binding to ES complex) is a mechanism detail but is not the **best** discriminator; the reversibility by substrate concentration is the most clinically and practically useful distinguishing feature.